Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63+0.00 (+0.13%)
Close on Nov 18, 2026Market cap $23.87MP/E –Yield –
Metagenomi Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Metagenomi Therapeutics's revenue for the twelve months ending Mar 31, 2026 was $22.33M, down 50.7% year over year. For fiscal 2025 it was $25.21M, down 51.8% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.21M | -51.8% |
| FY2024 | Dec 31, 2024 | $52.30M | +16.8% |
| FY2023 | Dec 31, 2023 | $44.76M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $1.25M | -69.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.91M | -59.3% |
| Q3 FY2025 | Sep 30, 2025 | $8.66M | -24.8% |
| Q2 FY2025 | Jun 30, 2025 | $8.51M | -57.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.13M | -63.0% |
| Q4 FY2024 | Dec 31, 2024 | $9.61M | -22.5% |
| Q3 FY2024 | Sep 30, 2024 | $11.51M | -6.9% |
| Q2 FY2024 | Jun 30, 2024 | $20.01M | +76.5% |
| Q1 FY2024 | Mar 31, 2024 | $11.16M | +28.9% |
| Q4 FY2023 | Dec 31, 2023 | $12.40M | – |
| Q3 FY2023 | Sep 30, 2023 | $12.36M | – |
| Q2 FY2023 | Jun 30, 2023 | $11.34M | – |
| Q1 FY2023 | Mar 31, 2023 | $8.66M | – |
See a number that looks wrong?